Topic 20 · Everything else

Revision Surgery Outcomes

The central question for this ankle. Success drops with each revision, and the 806-ankle non-primary review is the best evidence that exists.

→ "Revision" = doing surgery again after a first surgery failed. Success rates are lower than first-time surgery. The more revisions, the harder it gets.

2024 Comprehensive Revision Systematic Review (50 Studies, 806 Ankles)

The largest pooled analysis of non-primary OLT procedures to date [148]:

22%
Pooled clinical failure (revision cases)
ACI & OAT
Best revision PRO performance
28%
HemiCAP failure rate (worst)
19%
OCA failure rate in revision

BMS for Non-Primary/Revision OLT

A systematic review found concerning outcomes for revision cases [21]:

61%
Success rate (vs 82% primary)
27%
Re-revision rate

2026 Non-Primary BMS Prospective Study

A new 2026 prospective study confirmed that non-primary BMS improves patients from baseline but still underperforms primary cases at 2 years [149].

Realignment Surgery for Failed OAT (2024)

When osteochondral autograft transplantation fails with concomitant malalignment [134]:

Repeat Arthroscopy and Microfracture (2024)

A study on repeat procedures found [135]:

2026: The Nerve-Injury Risk of the Arthroscopy Itself (545 Procedures)

→ This is not about whether a repair works. It is about the numbness and burning that can follow simply from the camera portals — a risk that applies to every option on this page, because they all start with an arthroscopy.

A retrospective cohort of 545 consecutive ankle and hindfoot arthroscopies at a single referral centre (October 2023–May 2025) tracked sensory nerve complications and, unusually, followed their course [238]:

8.4%
Sensory nerve complications (46 of 545)
65%
Superficial peroneal nerve (sural 24%)
44.4%
Fully resolved at mean 13 months
84.4%
Improving, though not resolved

Why this belongs on this page. Every option still under consideration — the MASCOT trial, osteochondral autograft, bone marrow stimulation, TOPIC, a diagnostic look-and-see, even a “just clean it out” procedure — begins with an ankle arthroscopy. The rate itself is in the range usually quoted; the finding that matters is that fewer than half of those affected were fully better more than a year later. That reframes portal nerve injury from a transient nuisance into a real and reasonably common cost that belongs in the decision, and it is a specific question worth asking any surgeon proposing a procedure: what is your rate, and by what approach. Caveats: Level IV, retrospective, one centre, and a mixed case load rather than isolated talar lesions — so the absolute percentage may not transfer even if the recovery pattern does.

Key point: Revision success rates are consistently lower than primary surgery. The 2024 pooled review shows OAT and ACI outperform OCA and HemiCAP in revision settings, but all revision approaches carry meaningful failure risk.